Endocrine Changes Associated with Relapse in Advanced Breast Cancer Patients on Aminoglutethimide Therapy

Publisher Website
Google Scholar
Abstract
About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs. In this study, 36 patients who initially responded to this treatment were evaluated to determine whether clinical relapse was associated with escape from endocrine suppression. Plasma estrone levels rose significantly (mean increase, 6.8 pg/ml) during the final 15 of time on treatment before relapse. Mean plasma estradiol, dehydroepiandosterone sulfate, and androstenedione levels also rose with the approach of the relapse, but the increases were not statistically significant. The increase in estrone may contribute to the progression of disease.